AACR-NCI-EORTC 2019 - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 26 - Oct 30, 2019 | BostonMAUS
LARVOL is not affiliated with AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and all trademarks, logos, and brand names are property of their respective owners
Showing 54 abstracts linked to Trials
Olaparib and the ATR inhibitor AZD6738 in relapsed, refractory cancer patients with homologous recombination (HR) repair mutations – OLAPCO
Phase IB combination study of copanlisib and nivolumab in advanced solid tumors and lymphomas
Safety and pharmacokinetic results from a phase 1, multicenter, open‑label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2‑positive breast cancer
Anti-angiogenic activity of the CXCR4 antagonist balixafortide
Clinical and analytic validation of FoundationOne CDx&[trade] for NTRK fusion-positive solid tumors in patients treated with entrectinib
Biomarker analysis of patients with MET&[Delta]ex14 mutated non-small-cell lung cancer (NSCLC) treated with capmatinib in the GEOMETRY mono-1 study
Association of tumor DNA in circulation with clinical characteristics and treatment response in HR+/HER2&[minus] advanced breast cancer
A phase 1/2a, open-label, dose-escalation study of EC-18 in patients with metastatic breast cancer for the prevention of chemotherapy-induced neutropenia
Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma
Using prebaseline and on-treatment tumor assessments to compare time to tumor size progression of hormonal therapy + sapanisertib vs an extrapolated hormonal therapy alone from a single-arm phase 2 study
Correlation of homologous recombination deficiency (HRD) status by BROCA-HR sequencing with response to combination cediranib and olaparib in relapsed ovarian cancer
FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations
FIGHT-101: A phase 1/2 study of pemigatinib, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, as monotherapy and as combination therapy in patients with advanced malignancies
National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies
A phase 1, first-in-human, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma